• Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 64 p. [67 references]

Does not apply to this measure

This measure is used to assess the percentage of adolescents who are on time with recommended immunizations (Hep B, Hep A, HPV [for females], MMR, MCV4, Tdap, VZV [for patients without evidence of immunity]).

The priority aim addressed by this measure is to increase the percentage of patients who are on time with recommended immunizations.

Immunization; hepatitis B (Hep B); hepatitis A (Hep A); human papillomavirus (HPV); measles, mumps and rubella (MMR); meningococcal (MCV4); tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap); varicella vaccine (VZV)

All adolescents age 12 to 17 with continuous enrollment who presented for a primary care visit in the specified quarter

Number of adolescents in denominator who are on time with recommended immunizations (see the related "Numerator Inclusions/Exclusions" field the Complete Summary)

• A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

Unspecified

Current routine use

Internal quality improvement

Physician Group Practices/Clinics

Physicians

Group Clinical Practices

Age 12 to 17 years

Either male or female

Unspecified

Unspecified

Unspecified

Unspecified

Unspecified

Unspecified

Staying Healthy

Effectiveness

Users of care only

Adolescents ages 12 to 17

This measure should be collected through:

• Identifying eligible adolescents who presented in the target quarter for a primary care visit who have maintained continuous enrollment for 18 months.
• Reviewing the record to determine if all recommended doses were given within 18 months of the first dose.

The suggested time period for data collection is quarterly.

Patients associated with provider

Inclusions
All adolescents age 12 to 17 with continuous enrollment who presented for a primary care visit in the specified quarter

Exclusions
Unspecified

All cases in the denominator are equally eligible to appear in the numerator

Encounter
Patient Characteristic

Time window is a single point in time

Inclusions
Number of adolescents in denominator who are on time with recommended immunizations*

*An adolescent is on time with recommended immunizations if he/she has received:

• Hep B -- hepatitis B vaccine
• Hep A -- hepatitis A vaccine
• HPV -- human papillomavirus vaccine (for females)
• MMR -- measles, mumps and rubella
• MCV4 -- meningococcal
• Tdap -- tetanus, diphtheria toxoids and acellular pertussis vaccine
• VZV -- varicella vaccine (for patients without evidence of immunity)

Note: Dosing schedule is subject to change, depending on manufacturer's recommendations. Refer to the Immunization table and corresponding annotations in the original measure documentation for specific administration criteria.

Exclusions
Unspecified

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

Fixed time period

Medical record

Individual Case

Unspecified

Rate

Better quality is associated with a higher score

Unspecified

Internal time comparison

Unspecified

Percentage of adolescents who are on time with recommended immunizations.

• Hep B -- hepatitis B vaccine
• Hep A -- hepatitis A vaccine
• HPV -- human papillomavirus vaccine (for females)
• MMR -- measles, mumps and rubella
• MCV4 -- meningococcal
• Tdap -- tetanus, diphtheria toxoids and acellular pertussis vaccine
• VZV -- varicella vaccine (for patients without evidence of immunity)

Institute for Clinical Systems Improvement

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

Work Group Members: James Nordin, MD (Work Group Leader) (HealthPartners Medical Group) (Pediatrics); Emma Carlin, MD (Park Nicollet Health Services) (Family Medicine); Barbara Yawn, MD (Olmsted Medical Center) (Family Medicine); Abinash Virk, MD (Mayo Clinic) (Infectious Disease); Barb Ottis, RN (Park Nicollet Health Services) (Nursing); Renner Anderson, MD (Park Nicollet Health Services) (Pediatrics); Robert Jacobson, MD (Mayo Clinic) (Pediatrics); Sarah Rall, PharmD (Marshfield Clinic) (Pharmacy); Penny Fredrickson (Institute for Clinical Systems Improvement) (Measurement/Implementation Advisor); Melissa Marshall, MBA (Institute for Clinical Systems Improvement) (Facilitator)

ICSI has adopted a policy of transparency, disclosing potential conflict and competing interests of all individuals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee and Respiratory Steering Committee).

Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.

Dr. Robert Jacobson serves on the data safety monitoring board for Kaiser Permanente of Southern California overseeing a Gardasil trial. He receives less than $10,000 for this commitment.

Barbara Ottis, RN holds stock in Merck and Baxter. She also received speaker fees from GSK in an amount less than $10,000.

Dr. Barbara Yawn negotiated research funds on behalf of Olmsted Medical Center from Merck. Dr. Yawn receives less than $10,000 from Merck for serving on the advisory board for Zostravax.

No other work group members have potential conflicts of interest to disclose.

Measure was not adapted from another source.

2003 Jul

2008 Oct

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Oct. 67 p.

• Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 64 p. [67 references]

This NQMC summary was completed by ECRI on April 19, 2004. This NQMC summary was updated by ECRI Institute on October 11, 2004, August 11, 2005, July 17, 2006, December 26, 2007 and again on November 26, 2008.

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.